Search clinical trials for: new thermo stable formulation of epoprostenol sodium

Total 538 results

GlaxoSmithKline

Completed

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

Hypertension, Pulmonary

United States, Netherlands, Canada
Takeda

Completed

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

Hypothyroidism

Belgium
Allergan

Completed

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Dry Eye Syndromes

Canada, Australia
Boehringer Ingelheim

Terminated

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Healthy
Pfizer

Completed

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Healthy

United States
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
Allergan

Completed

A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery

Bilateral LASIK Surgery

Australia, Canada
Lung Biotechnology PBC

Completed

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Czechia, Germany, Ireland, Romania
ViiV Healthcare

Completed

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
EMD Serono

Completed

Rebif New Formulation (RNF) Quality of Life (QOL) Study (RebiQoL)

Relapsing Multiple Sclerosis

United States
Lung Biotechnology PBC

Completed

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Ireland
Akebia Therapeutics

Completed

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

Healthy

United States
AbbVie (prior sponsor, Abbott)

Completed

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Rheumatoid Arthritis

United States, Belgium, Czech Republic, Germany, Puerto Rico, Romania, Slovakia
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

Healthy

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Healthy Participants

China
Pfizer

Recruiting

A Study for Two Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

Healthy Participants

United States
Bayer

Completed

Moisturizing Effect of Two Dexpanthenol Formulations

Skin Abnormalities

France
Boehringer Ingelheim

Completed

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Healthy
Bayer

Completed

Efficacy of Dexpanthenol in Thermic Erythema

Erythema

France
Sanofi

Completed

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes

Germany
Universitätsklinikum Hamburg-Eppendorf

Unknown

Neutrophil Extracellular Traps and Neonatal (PV4991) & Pediatric Sepsis (PV5063)

Sepsis

Germany
Opella Healthcare Group SAS, a Sanofi Company

Recruiting

Bioavailability Study of Fexofenadine HCl New Formulation Tablet

Healthy Volunteers

Canada
Montreal Heart Institute

Not yet recruiting

Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation (MILAN)

Right Ventricular Dysfunction | Right Heart Failure
Pfizer

Completed

A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.

Menopause | Vaginitis | Metrorrhagia | Primary Ovarian Insufficiency

Japan
Sanofi

Completed

Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

Diabetes Mellitus Type 2

Germany
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet

Healthy Volunteers

United States
Boehringer Ingelheim

Completed

Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

Healthy
Opella Healthcare Group SAS, a Sanofi Company

Not yet recruiting

Bioavailability Study of Magne-B6 New Formulation

Healthy Volunteers
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
Bristol-Myers Squibb

Completed

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Healthy Participants

United States
GlaxoSmithKline

Completed

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

Systemic Lupus Erythematosus

United States
GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
University of Maryland, Baltimore
University of Maryland, College Park

Terminated

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies (0805GCC)

Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Platinum Responsive Malignancies

United States
Heilongjiang Feihe Dairy Co. Ltd.

Completed

New Stage 1 Formula on Gut Comfort and Gut Health

Health Behavior

China
Pfizer
Ono Pharmaceutical Co. Ltd; Pierre Fabre Laboratories

Completed

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations (ERBA)

Healthy

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

Normal Volunteers

United States
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

Type 2 Diabetes Mellitus

United States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (EDITION II)

Type 2 Diabetes Mellitus

United States, Finland, South Africa, Canada, Mexico, Chile, Spain, Russian Federation, France, Germany, Hungary, Portugal, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy (EDITION III)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus (EDITION IV)

Type 1 Diabetes Mellitus

United States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Type 1 Diabetes Mellitus

United States
Merck KGaA, Darmstadt, Germany

Completed

Transition to Rebif New Formulation (TRANSFER)

Relapsing Multiple Sclerosis

France, Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

Healthy

Germany
Sanofi

Completed

Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Diwuweilong

Recruiting

Analgesic Effect of Peripheral Cutaneous Nerve Block of Knee Joint After Total Knee Arthroplasty

Analgesia | Arthroplasty, Replacement, Knee

China
Orphelia Pharma
Hospices Civils de Lyon; Institut National de la Santé Et de la Recherche Médicale... and other collaborators

Completed

Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy (SoluWest)

Infantile Spasms

France

3

Subscribe